With faailites in San Diego CA And Alachua, FL., Banyan Biomarkers, Inc. is structured around development of in vitro diagnostic products to detect traumatic brain injuries (TBIs): also known as concussion. Founded by scientists from the University of Florida McKnight Brain Institute, the effort has been to address the challenges in diagnosing TBI - that has been designated an âinvisible injuryâ because the patient may look fine but symptoms like headache, confusion, and sensitivity to light can be persistent. This unmet medical need has been the driving force to develop a blood based biomarker test for brain injury. With support from the US Department of Defense and researcher partners all over the world, Banyon Biomarkers has made progress towards validating the use of Ubiquitin C- terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) particularly to rule out the need for a computed tomography (CT) scan in adults presenting with a suspected head injury. An important breakthough was achieved in February 2018 when the FDA - the US Food and Drug Administration - designated the Banyan Brain Trauma Indicator® (BTI) as a Breakthrough Device specifically allowing the product to be marketed for the purpuse for which it was develo
